- Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates – UK — Recruiting • Oncology • NCT06869122.
- Sponsor: Creo Medical Limited.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and…
- : Patients who: 1. Have signed informed consent.
- Subject is willing and able to comply with all aspects of the treatment and evaluation schedule. 3. Are ≥ 18 years old. 4. Have lung lesion(s)/nodule(s) which are histopathological confirmed as cancer. 5. Have soft tissue lung lesion(s): * ≤ 20 mm in the largest dimension of the pulmonary window 6. Are candidates for surgical resection as determined by a multi-disciplinary team (MDT) or tumour board. 7. > 10 mm of tumour-free lung parenchyma between target tumour and pleura or fissure.
- Subject is willing and able to comply with the study protocol requirements. 9. Are assigned an ASA (American Society of Anaesthesiologists) score of ≤ 3 or the patient is deemed fit for general anaesthesia.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.